top of page
eXmoor Pharma

Click to Download


Wednesday, 11 October 2023

Press Release

Media Contacts:

IB Communications

Tel +44 (0)20 89434685

eXmoor completes expansion into full-service cell and gene therapy CDMO partner with opening of GMP facilities

Newly added manufacturing capabilities at eXmoor’s Cell and Gene Therapy Centre in Bristol, UK will help developers take advanced therapies from concept to clinic

Bristol, UK, October 11, 2023 – eXmoor pharma, the full-service cell and gene therapy (CGT) manufacturing partner, today launches its new Cell and Gene Therapy Centre GMP facility, to support the simultaneous production of multiple therapies for clinical trials. The cutting-edge, 65,000 sq ft facility – designed with the same extensive knowhow eXmoor has used to advise manufacturers for decades – offers much-needed capacity and capability to help scale the next generation of CGTs for human trials and beyond. The facility is the final step in eXmoor’s expansion into a full-service CGT contract development and manufacturing organization (CDMO).

“The opening of this facility marks a landmark achievement for us, as we bring our 19 years of translation consulting and process development experience to directly enable the rapid development of life changing therapies in the UK and beyond,” said Angela Osborne, CEO of eXmoor. “To date, we have completed more than 500 projects, including the design of 37 CGT manufacturing facilities. Our Cell and Gene Therapy Centre represents the culmination of all that experience.”

eXmoor has long been a sought-after consultancy for companies seeking to build GMP manufacturing facilities in the CGT space, and leaned into that expertise to quickly construct the new Bristol facility, in only 14 months.

The Cell and Gene Therapy Centre houses specialized labs for clients’ process and analytical development, with the capability for technology transfer to GMP production on the same site. The GMP area features:

  • Four large, Grade C processing modules with airlocks

  • Process-agnostic design for both cell and gene therapy manufacturing

  • Complete segregation between processing modules

  • Up to two-times 200L bioreactor scale for viral vector or allogeneic cell therapy manufacture or space for up to five autologous cell therapy stations

  • Fully serviced with all GMP gas supplies for any cell /gene therapy process

  • Uninterruptable power supply (UPS) and emergency generator for electrical back up

  • Expansion space of 12,000 sq ft for another nine suites to grow with eXmoor’s clients into scaled-up and -out manufacturing for pivotal trials and in-market supply

  • 6,500 sq ft for process development, quality control and analytical labs, with ‘same again’ expansion potential for additional manufacturing and commercialization partnerships.

The facility has also been designed with no fossil fuel usage on site, relying instead on solar technology and heat pumps.

eXmoor anticipates securing a Medicines and Healthcare products Regulatory Agency Manufacturing License in April 2024, allowing for the clinical manufacture of cell and gene therapies. The company is now scheduling 2024 manufacturing slots for developers that share eXmoor’s desire to accelerate therapies to patients in extreme need.

About eXmoor pharma

eXmoor pharma is a one-stop cell-and-gene-therapy partner accelerating the manufacturing journey from research to patients. Founded in 2004, eXmoor has specialized in the CGT sector since 2007, helping organizations to understand, plan and implement the appropriate CMC strategy. eXmoor does this via its combination of GMP manufacturing capability and its translation and capital consulting groups, including process and analytical development labs. eXmoor has completed over 500 projects for 150 organizations and is headquartered in Bristol, UK, with 80 current employees, growing to 200 by 2027. To learn more:

bottom of page